Immunovant, Inc. IMVT Balance Sheet Statement
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| $902.11M-9.3% | $994.53M+90.6% | $521.87M-12.9% | $598.91M-16.1% | $713.97M+90.6% | ||
| $1.13M-31.0% | $1.64M-16.6% | $1.97M+1.8% | $1.94M-7.1% | $2.08M-6.3% | ||
| $42.76M-8.6% | $46.77M-5.9% | $49.71M-2.4% | $50.92M-0.5% | $51.18M+43.6% | ||
| $948.82M-9.0% | $1.04B+81.8% | $573.55M-12.0% | $651.76M-15.1% | $767.66M+86.1% | ||
| $443K-16.6% | $531K-16.0% | $632K-14.2% | $737K-12.7% | $844K+12.2% | ||
| $7.68M-13.9% | $8.92M+1.6% | $8.78M-1.8% | $8.94M+17.4% | $7.62M0.0% | ||
| $957.01M-9.1% | $1.05B+80.5% | $582.96M-11.9% | $661.44M-14.8% | $776.22M+84.4% | ||
| $7.54M-12.5% | $8.62M+24.6% | $6.92M-11.8% | $7.84M-55.6% | $17.66M-10.9% | ||
| $175K-92.7% | $2.41M+43.3% | $1.68M-15.1% | $1.98M+624% | $273K-99.4% | ||
| $104.42M+57.6% | $66.26M+4.7% | $63.25M+19.6% | $52.9M-23.1% | $68.78M+0.7% | ||
| $104.42M+57.6% | $66.26M+4.7% | $63.25M+19.6% | $52.9M-23.1% | $68.78M+0.7% | ||
| $20K-100.0% | $500M0.0% | $500M0.0% | $500M+3,124,900% | $16K-100.0% | ||
| $2.6B+0.6% | $2.58B+28.8% | $2B+1.9% | $1.97B+1.1% | $1.95B+31.2% | ||
| -$1.75B-9.3% | -$1.6B-7.4% | -$1.49B-9.3% | -$1.36B-9.7% | -$1.24B-9.4% | ||
| $730K-39.0% | $1.2M-17.4% | $1.45M-16.5% | $1.74M+19.1% | $1.46M-41.1% | ||
| $852.59M-13.5% | $986.14M+89.7% | $519.71M-14.6% | $608.54M-14.0% | $707.45M+101% | ||
| $957.01M-9.1% | $1.05B+80.5% | $582.96M-11.9% | $661.44M-14.8% | $776.22M+84.4% | ||
| $7.68M-13.9% | $8.92M+1.6% | $8.78M-1.8% | $8.94M+17.4% | $7.62M0.0% | ||
| $7.68M-13.9% | $8.92M+1.6% | $8.78M-1.8% | $8.94M+17.4% | $7.62M0.0% | ||
| $7.68M-13.9% | $8.92M+1.6% | $8.78M-1.8% | $8.94M+17.4% | $7.62M0.0% | ||
| —— | $57.64M+2.3% | $56.34M+25.0% | $45.06M-11.9% | $51.12M— | ||
| $175K— | —— | —— | —— | $273K— | ||
| —— | $1.27M+48.4% | $857K+7.9% | $794K+0.6% | $789K+569% | ||
| —— | 203.3M+16.5% | 174.5M+2.0% | 171.1M+0.6% | 170.1M+15.6% | ||
| —— | $117.2M+144% | $48.09M-34.8% | $73.81M-17.0% | $88.96M-50.3% | ||
| —— | 10M0.0% | 10M0.0% | 10M— | —— | ||
| $20K0.0% | $20K+17.6% | $17K+6.3% | $16K0.0% | $16K+14.3% | ||
| —— | 5M-25.8% | 6.7M-29.9% | 9.6M— | —— | ||
| —— | $0.000.0% | $0.000.0% | $0.00— | —— | ||
| —— | 10.6M-17.9% | 12.9M-12.8% | 14.8M+14.0% | 13M-1.8% | ||
| —— | 22.8M-10.2% | 25.4M-12.0% | 28.9M+25.4% | 23M-1.7% | ||
| —— | $15.07+5.9% | $14.23+12.8% | $12.62+5.2% | $12.00+0.3% | ||
| —— | $14.08M+47.9% | $9.52M+94.0% | $4.91M-68.6% | $15.62M+38.8% | ||
| —— | $1.27M+48.4% | $857K+7.9% | $794K+0.6% | $789K+569% | ||
| —— | $0-100% | $671K-22.2% | $862K+216% | $273K— | ||
| —— | $38.67M-9.3% | $42.65M+20.3% | $35.44M+8.7% | $32.62M-8.3% | ||
| —— | $1.22M+27.1% | $958K-10.6% | $1.07M+308% | $263K— | ||
| —— | $22.84M-10.2% | $25.43M-12.0% | $28.89M+25.4% | $23.04M-1.7% | ||
| —— | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| —— | $500M0.0% | $500M0.0% | $500M0.0% | $500M0.0% | ||
| —— | $203.32M+16.5% | $174.53M+2.0% | $171.07M+0.6% | $170.11M+15.6% | ||
| —— | $203.32M+16.5% | $174.53M+2.0% | $171.07M+0.6% | $170.11M+15.6% | ||
| —— | 10K0.0% | 10K0.0% | 10K0.0% | 10K0.0% | ||
| —— | $32.5M0.0% | $32.5M0.0% | $32.5M— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $2.41M+43.3% | $1.68M-15.1% | $1.98M+27.2% | $1.55M+2.1% | ||
| —— | $00.0% | $00.0% | $0— | —— | ||
| —— | $10.01M0.0% | $10.01M0.0% | $10.01M— | —— | ||
| $42.76M-8.6% | $46.77M-5.9% | $49.71M-2.4% | $50.92M-0.5% | $51.18M+43.6% | ||
| —— | $5.01M-25.8% | $6.75M-29.9% | $9.62M— | —— | ||
| —— | $10.59M-17.9% | $12.89M-12.8% | $14.78M+14.0% | $12.96M-1.8% | ||
| —— | $15.07+5.9% | $14.23+12.8% | $12.62+5.2% | $12+0.3% | ||
| —— | $7.63M+3.5% | $7.38M-14.1% | $8.59M+42.5% | $6.03M+1.5% | ||
| —— | $117.2M+144% | $48.09M-34.8% | $73.81M-17.0% | $88.96M-50.3% | ||
| —— | $12.32+9.1% | $11.29+13.2% | $9.97— | —— | ||
| —— | $69.04M+69.0% | $40.86M-37.4% | $65.23M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Immunovant, Inc.'s total assets?
- Immunovant, Inc. (IMVT) holds $957.0M in total assets, up 23.3% year over year.
- How much debt does Immunovant, Inc. have?
- Immunovant, Inc. carries $72.0K in total debt against $852.6M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Immunovant, Inc. have?
- Immunovant, Inc. holds $902.1M in cash and equivalents.
- Can Immunovant, Inc. cover its short-term obligations?
- Its current ratio is 9.09 — current assets exceed current liabilities.
- Where does Immunovant, Inc.'s balance sheet data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.